Becton, Dickinson and Company (BDX) Balance Sheet

The reduction in total assets and debt appears to reflect the Embecta spin-off and ongoing debt repayment, as total debt declined from $21.6B to $16.8B over the same period. This deleveraging, combined with a stable equity base around $24-25B, suggests a strengthening balance sheet trajectory, though the pace may be influenced by activist pressure for strategic changes.

While the D/E ratio is now below the peer average (e.g., Baxter at 1.64), BDX's absolute debt load is significant, and the cash position is thin relative to debt, suggesting limited near-term liquidity buffer. The reduction in debt appears strategic, but the company's ability to refinance at favorable rates may be challenged in a higher-rate environment, warranting monitoring of interest coverage.

The high goodwill concentration, largely from the Bard and CareFusion acquisitions, exposes the balance sheet to potential impairment risk if growth platforms underperform. The modest PPE base suggests a manufacturing model that relies on outsourced or efficient production, but the decline in PPE from $7.0B in 2025Q4 may indicate reduced capital investment, which could impact long-term capacity.

The modest growth in retained earnings, despite significant capital returns ($2.2B buybacks in 2026Q3 per cash flow data), indicates that BDX is returning most of its earnings to shareholders. This may signal confidence in cash generation, but it also limits internal reinvestment, which could be a concern given the need for R&D and regulatory remediation.

The current ratio below 1.0 suggests that BDX may struggle to cover short-term liabilities with current assets, a deterioration from prior levels. The sharp decline in cash, despite stable operations, may be due to debt repayment and capital returns, but it reduces the buffer against operational shocks. Investors should monitor whether this trend reverses or if the company relies on credit lines.